graft rejection: Definition, Uses, and Clinical Overview

graft rejection Introduction (What it is)

graft rejection is an immune response in which the body recognizes a transplanted tissue (a graft) as foreign and attacks it.
In eye care, it most often refers to rejection after corneal transplantation (keratoplasty).
It can also apply to other ocular surface or eye-adjacent grafts, such as patch grafts used to repair thinning tissues.
Clinicians use the term to describe a specific cause of graft dysfunction that may be reversible if identified early.

Why graft rejection used (Purpose / benefits)

graft rejection is not a treatment that is “used” like a medication or device. Instead, it is a clinical concept used to:

• Explain a common transplant-related complication. After ocular tissue is transplanted, the immune system may react against donor cells or proteins, causing inflammation and reduced graft function.
• Guide monitoring after surgery. Recognizing graft rejection as a possibility shapes follow-up planning, symptom education, and examination priorities.
• Support early recognition and timely care. Many graft problems look similar at first (blurred vision, redness, irritation). Labeling a presentation as possible graft rejection helps clinicians prioritize evaluation for immune-mediated causes.
• Differentiate rejection from other causes of graft failure. Not all graft failure is rejection. Infection, elevated eye pressure, suture problems, surface dryness, and recurrence of the original disease can also reduce graft clarity or function.
• Improve long-term outcomes by clarifying risk and prevention strategies. The term helps frame discussions about immunologic risk, the role of anti-inflammatory therapy, and the importance of ongoing monitoring, without implying a guaranteed outcome.

In ophthalmology, the key “benefit” of understanding graft rejection is better clinical decision-making around transplant health—especially because immune-mediated injury may sometimes be limited or reversed, depending on the graft type and clinical scenario.

Indications (When ophthalmologists or optometrists use it)

Clinicians consider graft rejection when evaluating or counseling patients in situations such as:

• New or worsening blurred vision after corneal transplantation (penetrating keratoplasty, DALK, DMEK, DSAEK)
• Eye redness, light sensitivity (photophobia), discomfort, or tearing in an eye with a prior graft
• New corneal swelling (edema), haze, or inflammation seen on slit-lamp examination after transplantation
• Unexplained decrease in graft clarity or a change in corneal thickness on imaging
• Follow-up planning for patients at higher immunologic risk (varies by clinician and case)
• Assessment after changes in steroid or immunosuppressive regimens that might alter immune control (clinical context varies)
• Evaluation of other ocular grafts (for example, scleral or corneal patch grafts) if inflammation suggests an immune reaction

Contraindications / when it’s NOT ideal

Because graft rejection is a diagnosis/clinical event rather than a procedure, “contraindications” apply mainly to when it is not the best explanation for a graft problem. Situations where another cause may be more likely include:

• Infectious keratitis or endophthalmitis (infection can mimic or coexist with immune rejection, and the distinction matters for management)
• Primary graft failure (when a graft never clears or functions from the early postoperative period; mechanisms differ from classic immune rejection)
• Mechanical or surface-related problems, such as suture-related irritation, epithelial defects, significant ocular surface disease, or exposure problems
• Elevated intraocular pressure (IOP) causing corneal edema or endothelial stress, which may resemble rejection-related swelling
• Recurrence of the original corneal disease (for example, some dystrophies or inflammatory conditions) affecting graft clarity
• Toxic or medication-related surface injury that inflames the eye without a primary immune reaction against the graft
• Interface issues after lamellar surgery (for example, haze, scarring, or fluid at a surgical interface) that can reduce vision without being rejection

In practice, clinicians often keep graft rejection on the differential diagnosis while actively ruling out infections, pressure-related corneal edema, and surface disease.

How it works (Mechanism / physiology)

Immune mechanism (high level)

graft rejection occurs when the immune system identifies donor tissue as “non-self.” Immune cells and inflammatory signals can then target graft components, leading to tissue swelling, reduced transparency, and decreased function.

The eye has features of immune privilege, meaning it can sometimes limit inflammatory responses to protect vision. However, surgery, inflammation, blood vessel growth into the cornea (neovascularization), infections, and certain systemic immune conditions can reduce this immune privilege and increase the likelihood of rejection (varies by clinician and case).

Relevant anatomy and tissues

In ophthalmology, graft rejection most commonly involves the cornea, the clear front window of the eye. The cornea has multiple layers:

• Epithelium (outer skin-like layer)
• Stroma (thick, clear middle layer)
• Endothelium (inner single-cell layer that helps keep the cornea dehydrated and clear)

Rejection can primarily affect different layers depending on the transplant type:

• In endothelial keratoplasty (DMEK/DSAEK), the endothelium is central, so immune injury often presents with corneal edema and reduced clarity.
• In penetrating keratoplasty (full-thickness), multiple layers may be involved, and clinical signs can include endothelial inflammation and stromal haze.
• In anterior lamellar procedures (like DALK), rejection patterns differ because donor endothelium is not transplanted; immune reactions can still occur but the classic endothelial rejection picture may be less prominent.

Other ocular grafts (for example, patch grafts) involve different tissues and immune environments, so presentation and consequences can differ.

Onset, duration, and reversibility

There is no single “onset time” for graft rejection. It can occur relatively soon after surgery or much later; timing varies by graft type, immune risk, and postoperative course. The concept of “duration” is also variable: episodes may resolve, recur, or progress.

“Reversibility” depends on which cells are damaged and how quickly inflammation is controlled. Some types of corneal graft injury (especially involving the endothelium) can lead to lasting loss of function if enough cells are lost, while other inflammatory changes may improve. Outcomes vary by clinician and case.

graft rejection Procedure overview (How it’s applied)

graft rejection is not a surgical procedure. It is a clinical diagnosis and management pathway used after a graft has been placed. A typical high-level workflow looks like this:

1. Evaluation / exam – Symptom review (blurred vision, redness, discomfort, light sensitivity) – Visual acuity and basic eye measurements – Slit-lamp examination to assess graft clarity, corneal swelling, inflammation, sutures (if present), and surface integrity – Measurement of intraocular pressure (because pressure-related edema can mimic rejection)

2. Preparation – Review of transplant type and timeline (penetrating vs lamellar procedures) – Review of current and recent eye drops, especially anti-inflammatory therapy – Consideration of risk factors (ocular surface inflammation, corneal blood vessels, prior rejection episodes)

3. Intervention / testing (as clinically needed) – Imaging or measurements to document corneal thickness/clarity (varies by clinic) – Additional testing to evaluate infection or other causes if suspected (varies by clinician and case)

4. Immediate checks – Reassessment for coexisting conditions such as infection, high IOP, epithelial defects, or loose sutures – Documentation of baseline findings for comparison at follow-up

5. Follow-up – Close monitoring of symptoms and clinical signs over time – Ongoing assessment of graft clarity and function – Long-term planning to reduce recurrence risk when possible (approach varies by clinician and case)

Because graft rejection can resemble other urgent conditions, clinicians typically prioritize distinguishing immune rejection from infection and pressure-related problems.

Types / variations

graft rejection can be described in several ways, depending on the transplanted tissue and the clinical pattern.

By tissue and surgery type (common in cornea)

• Penetrating keratoplasty (PK) rejection: full-thickness grafts can show endothelial inflammation and corneal edema, sometimes with visible inflammatory patterns on examination.
• Endothelial keratoplasty (DMEK/DSAEK) rejection: involves the inner endothelial layer, often presenting with corneal swelling and reduced clarity.
• Anterior lamellar keratoplasty (DALK) immune reactions: because the recipient endothelium remains, classic endothelial rejection is less typical, but immune-mediated inflammation can still affect graft clarity and comfort.

By corneal layer pattern (descriptive)

• Epithelial rejection: outer layer involvement; may be subtler and sometimes overlaps with surface irritation.
• Stromal rejection: inflammation and haze within the corneal stroma.
• Endothelial rejection: a major concern because endothelial cells are critical for corneal clarity; injury may lead to persistent edema if cell loss is significant.

By timing (broad clinical framing)

• Acute rejection episodes: relatively sudden inflammatory changes.
• Chronic immune-mediated failure: longer-term immune injury that gradually reduces graft function.
• Hyperacute rejection: a well-known concept in some organ transplants; in corneal transplantation it is not typically discussed in the same way, and terminology usage varies by clinician and case.

By anatomic location beyond the cornea (less common, context-dependent)

• Patch graft inflammation (e.g., scleral or corneal patch grafts): may be described as immune reaction or graft melt/inflammation depending on findings and material used. Presentation and terminology vary by material and manufacturer.

Pros and cons

Pros:

• Provides a clear framework for explaining graft-related inflammation after transplantation
• Helps clinicians prioritize urgent causes of decreased graft clarity
• Encourages structured follow-up and documentation over time
• Supports layer-specific thinking (epithelium vs stroma vs endothelium) that matches transplant technique
• Helps separate immune-mediated dysfunction from mechanical, infectious, or pressure-related problems
• Improves communication between providers (optometry, cornea specialists, primary care teams)

Cons:

• Can be confused with non-immune “graft failure,” leading to misunderstandings about cause
• Symptoms overlap with infection and dry eye, so misclassification is possible without careful evaluation
• The term can sound definitive even when diagnosis is probabilistic early on
• Different graft types have different rejection patterns, making generalization difficult
• Some immune injury may not be fully reversible, depending on tissue layer and severity
• Anxiety-provoking for patients because “rejection” implies loss, even though outcomes vary by case

Aftercare & longevity

Aftercare following ocular transplantation is focused on maintaining graft health and detecting changes early. In the context of graft rejection, longevity is influenced by multiple interacting factors:

• Type of graft and surgical technique. Different corneal transplant approaches carry different patterns of immune risk and different clinical signs.
• Baseline diagnosis and ocular inflammation. Conditions associated with surface inflammation, scarring, or corneal blood vessels may increase immune activation risk (varies by clinician and case).
• Ocular surface health. Dry eye disease, blepharitis, exposure, and recurrent epithelial defects can increase surface inflammation and complicate interpretation of symptoms.
• Medication adherence and tolerability. Post-transplant anti-inflammatory regimens are individualized; missed doses, side effects, and access issues can affect inflammatory control (varies by clinician and case).
• Follow-up consistency. Regular exams allow comparison over time—often essential because early findings may be subtle.
• Intraocular pressure control. Elevated pressure can damage the cornea and mimic rejection-related swelling, and some anti-inflammatory drops can affect IOP in susceptible individuals.
• Comorbidities and immune status. Systemic autoimmune disease, atopy, and use of systemic immunosuppressants can influence inflammation and healing; the net effect varies by clinician and case.
• Previous rejection episodes. Prior immune episodes may increase vigilance needs, but long-term outcomes still vary widely.

Overall, graft longevity is not determined by a single factor. It reflects ongoing balance between immune activity, ocular surface stability, and postoperative care.

Alternatives / comparisons

Because graft rejection is a complication rather than a therapy, “alternatives” usually refer to alternative explanations, preventive strategies, or different surgical options that may have different rejection profiles.

graft rejection vs non-immune graft failure

• graft rejection implies immune-mediated inflammation directed at graft tissue.
• Non-immune graft failure may result from primary graft failure, chronic endothelial cell loss, pressure-related edema, mechanical issues, or recurrence of underlying disease.
• Clinically, both can present with blurred vision and corneal haze, so careful examination and history are used to differentiate them.

Monitoring/observation vs active treatment

• Some mild or ambiguous changes may be monitored closely to clarify the cause, while more convincing inflammatory patterns may prompt a more active anti-inflammatory approach. The threshold varies by clinician and case.
• Monitoring is also used after an episode to detect recurrence or progression.

Medication-focused approaches vs procedural approaches

• Immune-mediated episodes are often addressed with anti-inflammatory or immunomodulating medications (topical, and sometimes systemic in select cases). Specific choices vary by clinician and case.
• If a graft loses function despite medical control of inflammation, additional procedures may be considered, such as repeat keratoplasty or, in select settings, keratoprosthesis. Suitability varies by diagnosis and ocular surface status.

Different transplant choices and rejection patterns

• Lamellar keratoplasty (partial-thickness) can reduce certain risks compared with full-thickness transplantation in selected indications, but it introduces its own interface considerations.
• Endothelial keratoplasty replaces only the dysfunctional endothelial layer in appropriate conditions and has distinct rejection signs compared with PK.
• The “best” approach depends on the corneal disease being treated, ocular anatomy, and surgeon preference; outcomes vary by clinician and case.

graft rejection Common questions (FAQ)

Q: Is graft rejection the same as graft failure?
Not exactly. graft rejection refers to immune-mediated attack on the graft, while graft failure is a broader term meaning the graft is not functioning or is no longer clear. Rejection can lead to failure, but failure can also happen for non-immune reasons.

Q: What symptoms might suggest graft rejection in the eye?
Commonly discussed symptoms include new blur, redness, light sensitivity, and discomfort in an eye with a prior graft. These symptoms are not specific and can also occur with dry eye, infection, or pressure problems. Diagnosis relies on an eye examination and clinical context.

Q: Can graft rejection happen years after a corneal transplant?
Yes, it can occur long after surgery in some cases. Risk depends on graft type, ocular surface inflammation, corneal blood vessels, and other factors that vary by clinician and case. This is one reason long-term follow-up is often part of transplant care.

Q: Is graft rejection painful?
It can be uncomfortable and associated with irritation or light sensitivity, but experiences vary. Some people notice mainly blurred vision without significant pain. Symptom severity does not always match clinical severity.

Q: How is graft rejection diagnosed?
Diagnosis is primarily clinical, using history and slit-lamp examination. Clinicians look for patterns of inflammation and graft swelling and also assess for competing diagnoses like infection or elevated eye pressure. Additional tests may be used depending on the presentation and clinic resources.

Q: Is graft rejection “curable”?
Some rejection episodes can improve with prompt control of inflammation, but outcomes depend on the layer involved and the degree of tissue injury. If many endothelial cells are lost, corneal clarity may not fully recover. Prognosis varies by clinician and case.

Q: How long does recovery take after a rejection episode?
The timeline varies widely. Some changes improve over days to weeks, while others require longer monitoring to understand the lasting effect on graft clarity. Recovery also depends on whether other issues (like surface disease or pressure changes) are present.

Q: What is the cost range for evaluation or treatment of graft rejection?
Costs vary by location, insurance coverage, transplant type, clinic setting, and whether urgent visits, imaging, laboratory testing, or procedures are required. Medication coverage and the need for frequent follow-ups can also affect total cost. Clinics typically provide cost estimates based on the care plan.

Q: Can I drive or use screens if graft rejection is suspected?
Vision may be temporarily reduced due to corneal swelling or inflammation, which can affect tasks like driving. Screen use is not inherently harmful to a graft, but discomfort and blur can limit tolerance. Functional safety decisions depend on real-world vision and local driving requirements.

Q: Does graft rejection mean I will need another transplant?
Not necessarily. Some episodes resolve with treatment and careful follow-up, while others cause lasting graft dysfunction. The need for repeat surgery depends on how much function returns and on the underlying eye condition, which varies by clinician and case.